Molecular diagnostics revenues rose 5 percent driven in part by growth in infectious disease testing, a core area of diagnostic market focus for the firm.
The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.
The firm's overall growth in the quarter was led largely by 9 percent growth in its Diagnostics and Genomics Group.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
Product revenues were up 63 percent year over year, while research revenues rose twelvefold. The company placed nine new T2Dx instruments in Q2 2018.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.